160 related articles for article (PubMed ID: 38487528)
1. A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers.
Kenney RT; Cini JK; Dexter S; DaFonseca M; Bingham J; Kuan I; Chawla SP; Polasek TM; Lickliter J; Ryan PJ
Front Immunol; 2024; 15():1362775. PubMed ID: 38487528
[TBL] [Abstract][Full Text] [Related]
2. SON-1210 - a novel bifunctional IL-12 / IL-15 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy.
Cini JK; Dexter S; Rezac DJ; McAndrew SJ; Hedou G; Brody R; Eraslan RN; Kenney RT; Mohan P
Front Immunol; 2023; 14():1326927. PubMed ID: 38250068
[TBL] [Abstract][Full Text] [Related]
3. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
4. Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose Study.
Hug BA; Matheny CJ; Burns O; Struemper H; Wang X; Washburn ML
Clin Ther; 2020 Aug; 42(8):1519-1534.e33. PubMed ID: 32739049
[TBL] [Abstract][Full Text] [Related]
5. A randomized dose-escalation study on the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of a novel recombinant human albumin in healthy subjects.
Li C; Xiang W; Wu M; Zhang H; Cheng J; Yang T; Mai J; Chi X; Gao X; Ding Y; Niu J
Eur J Pharm Sci; 2021 Oct; 165():105923. PubMed ID: 34229078
[TBL] [Abstract][Full Text] [Related]
6. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
[TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
8. A first-in-human study to evaluate the safety, tolerability and pharmacokinetics of RP3128, an oral calcium release-activated calcium (CRAC) channel modulator in healthy volunteers.
Barde PJ; Viswanadha S; Veeraraghavan S; Vakkalanka SV; Nair A
J Clin Pharm Ther; 2021 Jun; 46(3):677-687. PubMed ID: 33314326
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects.
Danto SI; Shojaee N; Singh RSP; Li C; Gilbert SA; Manukyan Z; Kilty I
Arthritis Res Ther; 2019 Dec; 21(1):269. PubMed ID: 31805989
[TBL] [Abstract][Full Text] [Related]
11. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects.
Önnestam K; Nilsson B; Rother M; Rein-Hedin E; Bylund J; Anderer P; Kemethofer M; Halldin MM; Sandin J; Segerdahl M
J Prev Alzheimers Dis; 2023; 10(4):778-789. PubMed ID: 37874100
[TBL] [Abstract][Full Text] [Related]
12. Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
Daveson AJM; Ee HC; Andrews JM; King T; Goldstein KE; Dzuris JL; MacDougall JA; Williams LJ; Treohan A; Cooreman MP; Anderson RP
EBioMedicine; 2017 Dec; 26():78-90. PubMed ID: 29191561
[TBL] [Abstract][Full Text] [Related]
13. A Phase 1 Single-Ascending-Dose Trial in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravenous PNT001, a Novel Mid-domain Tau Antibody Targeting cis-pT231 Tau.
Luca W; Foster K; McClure K; Ahlijanian MK; Jefson M
J Prev Alzheimers Dis; 2024; 11(2):366-374. PubMed ID: 38374743
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice.
Melder RJ; Osborn BL; Riccobene T; Kanakaraj P; Wei P; Chen G; Stolow D; Halpern WG; Migone TS; Wang Q; Grzegorzewski KJ; Gallant G
Cancer Immunol Immunother; 2005 Jun; 54(6):535-47. PubMed ID: 15592670
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers.
Hu Y; Zhang H; Li X; Mai J; Yang L; Yan J; Li Y; Sun J; Xu W; He S; Li J; Wu M
Expert Opin Investig Drugs; 2022 Sep; 31(9):977-985. PubMed ID: 34633260
[TBL] [Abstract][Full Text] [Related]
16. Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study.
Li Y; Toyama K; Nakatsu T; Ishizuka H; Wu H; Cao G; Yu J; Wang Y; Liu X; Guo B; Wu J; Yu P; Hong Z; Zhang J; Wu X
Adv Ther; 2023 Apr; 40(4):1628-1643. PubMed ID: 36790683
[TBL] [Abstract][Full Text] [Related]
17. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study.
Klaus B; Sachse R; Ammer N; Kelepouris N; Ostrow V
Growth Horm IGF Res; 2020 Jun; 52():101321. PubMed ID: 32325373
[TBL] [Abstract][Full Text] [Related]
19. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers.
Cardinal M; Kantaridis C; Zhu T; Sun P; Pittman DD; Murphy JE; Arkin S
J Thromb Haemost; 2018 Sep; 16(9):1722-1731. PubMed ID: 29908043
[TBL] [Abstract][Full Text] [Related]
20. Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants.
Bundrant L; Hunt TL; Banks P; Gopinathan S; Boehm KA; Kassler-Taub K; Tyle P; Wilson A; Warner C; Wason S
Clin Ther; 2021 Jun; 43(6):1029-1050. PubMed ID: 34108079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
